Pulmonary hypertension secondary to lung diseases, as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), is a relatively common condition with a bad prognosis. During the last World Congress in Nizza, detailed instructions about pulmonary hypertension secondary to lung diseases were provided. Long-term oxygen therapy is not able to normalize pulmonary artery pressure (PAP) values or to counteract vascular remodeling; the use of specific drug for pulmonary hypertension secondary to COPD or IPF, especially in severe forms, has often been suggested, but full indications have not yet been supplied.
|Translated title of the contribution||Pulmonary hypertension secondary to parenchimal lung diseases: Treatment perspectives|
|Number of pages||6|
|Journal||Rassegna di Patologia dell'Apparato Respiratorio|
|Publication status||Published - 2016|
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Pulmonary and Respiratory Medicine